Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis

Open access

Abstract

BACKGROUND: Depression is the single largest contributor to non-fatal health loss worldwide. Second-generation antidepressants are the first-line option for pharmacological management of depression. Optimising their use is crucial in reducing the burden of depression; however, debate about their dose dependency and their optimal target dose is ongoing. We have aimed to summarise the currently available best evidence to inform this clinical question. METHODS: We did a systematic review and dose-response meta-analysis of double-blind, randomised controlled trials that examined fixed doses of five selective serotonin reuptake inhibitors (SSRIs; citalopram, escitalopram, fluoxetine, paroxetine, and sertraline), venlafaxine, or mirtazapine in the acute treatment of adults (aged 18 years or older) with major depression, identified from the Cochrane Central Register of Controlled Trials, CINAHL, Embase, LILACS, MEDLINE, PsycINFO, AMED, PSYNDEX, websites of drug licensing agencies and pharmaceutical companies, and trial registries. We imposed no language restrictions, and the search was updated until Jan 8, 2016. Doses of SSRIs were converted to fluoxetine equivalents. Trials of antidepressants for patients with depression and a serious concomitant physical illness were excluded. The main outcomes were efficacy (treatment response defined as 50% or greater reduction in depression severity), tolerability (dropouts due to adverse effects), and acceptability (dropouts for any reasons), all after a median of 8 weeks of treatment (range 4-12 weeks). We used a random-effects, dose-response meta-analysis model with flexible splines for SSRIs, venlafaxine, and mirtazapine. FINDINGS: 28 554 records were identified through our search (24 524 published and 4030 unpublished records). 561 published and 121 unpublished full-text records were assessed for eligibility, and 77 studies were included (19 364 participants; mean age 42·5 years, SD 11·0; 7156 [60·9%] of 11 749 reported were women). For SSRIs (99 treatment groups), the dose-efficacy curve showed a gradual increase up to doses between 20 mg and 40 mg fluoxetine equivalents, and a flat to decreasing trend through the higher licensed doses up to 80 mg fluoxetine equivalents. Dropouts due to adverse effects increased steeply through the examined range. The relationship between the dose and dropouts for any reason indicated optimal acceptability for the SSRIs in the lower licensed range between 20 mg and 40 mg fluoxetine equivalents. Venlafaxine (16 treatment groups) had an initially increasing dose-efficacy relationship up to around 75-150 mg, followed by a more modest increase, whereas for mirtazapine (11 treatment groups) efficacy increased up to a dose of about 30 mg and then decreased. Both venlafaxine and mirtazapine showed optimal acceptability in the lower range of their licensed dose. These results were robust to several sensitivity analyses. INTERPRETATION: For the most commonly used second-generation antidepressants, the lower range of the licensed dose achieves the optimal balance between efficacy, tolerability, and acceptability in the acute treatment of major depression. FUNDING: Japan Society for the Promotion of Science, Swiss National Science Foundation, and National Institute for Health Research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2215-0366(19)30217-2

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Study selection
Figure 1 Study selectionCC BY · PubMed Central
Figure 2 Dose-outcome relationships for selective serotonin reuptake inhibitors (99 treatment groups) RR=risk ratio. Each tick on the x-axis represents the dose examined in a treatment group. The dotted lines represent 95% CIs.
Figure 2 Dose-outcome relationships for selective serotonin reuptake inhibitors (99 treatment groups) RR=risk ratio. Each tick on the x-axis represents the dose examined in a treatment group. The dotted lines represent 95% CIs.CC BY · PubMed Central
Figure 3 Dose-outcome relationships for venlafaxine (16 treatment groups) RR=risk ratio. Each tick on the x-axis represents the dose examined in a treatment group. The dotted lines represent 95% CIs.
Figure 3 Dose-outcome relationships for venlafaxine (16 treatment groups) RR=risk ratio. Each tick on the x-axis represents the dose examined in a treatment group. The dotted lines represent 95% CIs.CC BY · PubMed Central
Figure 4 Dose-outcome relationships for mirtazapine (11 treatment groups) RR=risk ratio. Each tick on the x-axis represents the dose examined in a treatment group. The dotted lines represent 95% CIs.
Figure 4 Dose-outcome relationships for mirtazapine (11 treatment groups) RR=risk ratio. Each tick on the x-axis represents the dose examined in a treatment group. The dotted lines represent 95% CIs.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 323

Metadata

Authors
Furukawa, T. A., Cipriani, A., Cowen, P. J., Leucht, S., Egger, M., & Salanti, G.
Affiliations
  • Kyoto University (JP)
  • Oxford Health NHS Foundation Trust (GB)
  • Warneford Hospital (GB)
  • Technical University of Munich (DE)
  • University of Bern (CH)
Corresponding author
Cipriani, Andrea
Venue
The Lancet Psychiatry
Publisher
Elsevier BV
Published
2019-07
Volume
6
Issue
7
Pages
601-609
ISSN
2215-0366 (ISSN-L)
OpenAlex
W2948548704
Cited by
322
References
30
Citations by year
2026: 26 · 2025: 54 · 2024: 59 · 2023: 39 · 2022: 46 · 2021: 50 · 2020: 33 · 2019: 15
FWCI
4.62
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by)
  • BORIS (University Library Bern) (submittedVersion, cc-by)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion, other-oa)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
  • Kyoto University Research Information Repository (Kyoto University) (submittedVersion, cc-by)
  • Bristol Research (University of Bristol) (submittedVersion, cc-by)
Funders
  • NIHR Oxford Biomedical Research Centre (BRC-1215-20005)
  • National Institute for Health Research (RP-2017-08-ST2-006)
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (179158)
  • Japan Society for the Promotion of Science (17K19808)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords
major depressive disorder, selective serotonin reuptake inhibitors, venlafaxine, mirtazapine, dose optimization, treatment response, tolerability, acceptability, citalopram, escitalopram, paroxetine, sertraline, fluoxetine, adverse effects
MeSH terms
Venlafaxine Hydrochloride, Mirtazapine, Major Depressive Disorder, Depressive Disorder, Major, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Randomized Controlled Trials as Topic, Selective Serotonin Reuptake Inhibitors, Serotonin Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. https://app.cochat.ai/papers/10.1016/s2215-0366(19)30217-2
The paper
Furukawa, T. A., Cipriani, A., Cowen, P. J., Leucht, S., Egger, M., & Salanti, G. (2019). Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(19)30217-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.